The Proteomics Revolution: Why Proteins Tell a Different Story Than Your Genes

Proteins Are Biology in Action

A human genome contains approximately 20,000–25,000 protein-coding genes. The human proteome — the full complement of proteins expressed at any given time — is estimated to contain hundreds of thousands of distinct proteins and protein variants, generated through alternative splicing, post-translational modifications, protein-protein interactions, and continuous environmental regulation. The genome is a fixed set of instructions interpreted differently in every cell type, at every developmental moment, in response to every environmental input. The proteome is what those instructions produce — and it changes continuously.

Genomics vs. Proteomics: What Each Answers

Proteomics and Aging: The Stanford SomaScan Study

A landmark 2019 study by Tony Wyss-Coray and colleagues at Stanford, published in Nature Medicine, used SomaScan to measure approximately 3,000 proteins in plasma samples from 4,263 individuals aged 18–95. Key findings:

• —Plasma protein composition changes dramatically across the lifespan, in three waves of particularly rapid change at approximately ages 34, 60, and 78
• —A subset of proteins predicts chronological age with high accuracy — a 'proteomic aging clock' analogous to epigenetic age testing
• —The proteins driving age-associated changes are enriched in pathways related to extracellular matrix remodeling, neurological function, and hormone signaling

UK Biobank: Disease Prediction at Scale

A 2023 study in Nature Aging analyzed Olink proteomics data (approximately 1,400 proteins) from 52,704 UK Biobank participants, with multi-year follow-up for disease incidence. Plasma protein profiles predicted incident cardiovascular disease, type 2 diabetes, COPD, kidney disease, liver disease, neurological disease, and cancer with high accuracy — superior to prediction models based on conventional risk factors alone. Incorporating proteomic data meaningfully improved risk discrimination beyond what genomic polygenic risk scores or standard clinical biomarkers provided.

Disease-Specific Applications

• —Neurodegenerative disease — amyloid-beta 40/42 ratio, p-tau217, and GFAP are now validated blood-based biomarkers for Alzheimer's pathology, transforming diagnosis from invasive lumbar puncture to accessible blood draws
• —Cardiovascular disease — GDF-15, NT-proBNP, troponin, and inflammatory cytokines in combination provide risk stratification superior to traditional lipid panels in multiple large cohort studies
• —Cancer detection — proteomics-based liquid biopsy approaches aim to identify tumor-derived protein signatures in plasma, complementing cfDNA-based MCED testing

Bottom Line

Proteins are biology in action — the functional output of the genome, shaped continuously by environment, lifestyle, disease, and aging. Large-scale proteomics now offers the ability to measure thousands of proteins simultaneously in a single blood draw. The emerging evidence demonstrates that proteomic profiles predict aging trajectory and disease risk with accuracy that surpasses genetic and conventional biomarker approaches in several domains. The technology is transitioning from research tool to clinical instrument. In the context of a comprehensive precision medicine evaluation, it adds the dynamic biological dimension that static genomic analysis cannot provide.

References

1. 1. Lehallier B, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med. 2019;25(12):1843–1850.
2. 2. Argentieri MA, et al. Proteomic aging clock predicts mortality and risk of common age-related diseases. Nat Aging. 2023;3(12):1501–1514.
3. 3. Hansson O, et al. Plasma phospho-tau181 in Alzheimer's disease. Lancet Neurol. 2020;19(7):563–564.
4. 4. Ganz P, et al. Development and validation of a protein-based risk score for cardiovascular outcomes. JAMA. 2016;315(23):2532–2541.